Knee Osteoarthritis
Conditions
Brief summary
The purpose of this study is to evaluate the effect of alendronate sodium vitamin D3 tablets compared with placebo on the improvement of joint structure and joint pain in participants with knee osteoarthritis. The treatment period of this study is one year and followed-up period is 2 years. The results of knee joint MRI will be evaluated by using the WORMS score.
Detailed description
This is a multi-center, randomized, double-blind, placebo-controlled study This study is planned to commence after obtaining Ethics Committee approval. participants will be randomised to a one-year course of alendronate sodium vitamin D3 tablets or placebo. 1:1 double blinded randomisation will be undertaken. This study plans to enroll 60 participants and will be carried out in three domestic centers (Peking Union Medical College Hospital, Zhongshan Hospital and The Third Affiliated Hospital of Southern Medical University) with a follow-up period of 2 years. As the main goal of this exploratory study is to evaluate the effect of alendronate sodium vitamin D3 tablets compared with placebo on the improvement of joint structure and joint pain in participants with knee osteoarthritis. The primary outcome measure is WORMS score of knee joint MRI at 6 months and 12 months.
Interventions
DRUGalendronate sodium vitamin D3 tablets
once per week for one year
DRUGPlacebo
once per week for one year
Sponsors
CSPC Ouyi Pharmaceutical Co., Ltd.
Peking Union Medical College Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with significant knee pain (pain score≥40mm on the 100mmVAS scale); 2. Male or female patients, between 50-75 years old; 3. MRI suggests bone marrow edema-like lesions; 4. Knee osteoarthritis (in accordance with the diagnostic criteria of American College of Rheumatology (ACR) and Chinese Orthopaedic Association); 5. Kellgren-Lawrence gradingⅠorⅡin X-ray;
Exclusion criteria
1. Other forms of active arthritis (such as rheumatoid arthritis or other inflammatory arthritis); 2. Taken non-steroidal anti-inflammatory drugs and central analgesics (such as opioids) within two weeks； 3. Liver function ALT or AST is 1.5 times the upper limit of normal； creatinine clearance \<35ml/min； 4. Pregnancy or suckling; 5. Serious heart disease, endocrine, digestive, mental, nervous system diseases or cancer; 6. Active ulcers and a history of upper gastrointestinal bleeding; 7. Esophageal motility disorders, such as esophageal tardiness or stenosis; 8. Renal dysfunction or osteomalacia; 9. Tobacco addiction (mean 10 cigarettes per day or more) or/and alcohol addiction (mean 50ml per day or more); 10. Fresh fracture in the last six months; 11. Serious illnesses and life expectancy\<2 years; 12. Allergic to study drugs; 13. Used any study drug or device within 30 days before randomization or within the drug half-life (whichever is longer); 14. Failure to take medication as required; 15. Replacement surgery in the near future; 16. Contraindications to MRI scans (e.g. implanted pacemakers, metal sutures, shrapnel or iron filings in the eyes, claustrophobia, knees too large to use coils); 17. Sensitive to or unsuitable for X-ray exposure (e.g. aplastic anemia, etc); 18. Poor dental health or dental surgery in the near future.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| WORMS score of knee joint MRI | The sixth month | WORM score of participants at the sixth month after enrollment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| WORMS score of knee joint MRI | The 24th month | WORM score of patients at the 24th month after enrollment |
| Pain intensity and symptom record | The second week | Pain intensity and symptom record of patients at the second week after enrollment |
| Quality of life (the MOS item short from health survey,SF-36 ) | The third month | SF-36 scale of patients at the third month after enrollment |
| bone density (lumbar spine, hip joint and knee joint) | The 12th month | bone density of patients at the 12th month after enrollment |
| Risk of knee replacement | The 12th month | Risk of knee replacement of patients at the 12th month after enrollment |
| Kellgren & Lawrence(KL) grading Score | The 12th month | KL-grading Score of patients at the 12th month after enrollment, 0 to Ⅳ, higher scores mean a worse outcome |
| Serum IL-6, TNF-a, erythrocyte sedimentation rate, C-reactive protein | The third month | Serum inflammatory factor of patients at the third month after enrollment, IL-6 and TNF-a were measured in pg/ml,erythrocyte sedimentation rate was measured in mm/h, C-reactive protein was measured in mg/dL. |
Countries
China
Contacts
Primary ContactHuiming Peng
Outcome results
None listed